Cerebain Biotech Signs Letter of Intent with PKG, Inc.

Aug. 25, 2020 12:30 UTC



COSTA MESA, Calif.--(BUSINESS WIRE)-- Cerebain Biotech Corp. (OTC: CBBT), (the “Company” or “Cerebain”) today announced that it has entered into a Letter of Intent to purchase the assets of PKG, Inc. (PKG).

PKG, Inc. was established in 1989 and is a privately held corporation based out of Meridian, ID. PKG, Inc. is a leading contract design, developer, and manufacturing company for system-level devices with expertise in human-machine interfaces focusing on healthcare, industrial, aerospace and government products. For the past 30 years PKG has been a major contributor in designing and manufacturing numerous and diverse devices for Fortune 500 companies, mid-size organizations, and start-up businesses. With complete in-house vertical integration, PKG provides its customers with all of their product development needs from R&D, design & development, verification & validation, final product manufacturing, product testing, service and warranty and end of life product support and transitioning.

About Cerebain Biotech Corp.

Cerebain Biotech Corp. (OTC: CBBT) is a development-stage medical device company focused on the creation and clinical development of a minimally invasive implantable device and a synthetic drug solution. The device leverages the clinically observable, positive impact that Omentum stimulation has on cognitive function as related to dementias, and in particular, Alzheimer’s disease. The corporate vision is based on these positive clinical observations. Visit us at www.cerebain.com or connect with us on Twitter and Facebook to learn more.

Forward-Looking Statements

This news release contains certain "forward-looking statements." Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. The forward-looking statements are also identified through the use of words "believe," enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict" "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company's reports filed with OTC Markets. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved.


Mr. Alan Klitenic
Cerebain Biotech Corp.


Source: Cerebain Biotech Corp.

Back to news